J
Jeremie Lincy
Researcher at Novartis
Publications - 18
Citations - 3217
Jeremie Lincy is an academic researcher from Novartis. The author has contributed to research in topics: Everolimus & Neuroendocrine tumors. The author has an hindex of 7, co-authored 18 publications receiving 2892 citations.
Papers
More filters
Journal ArticleDOI
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
James C. Yao,Manisha H. Shah,Tetsuhide Ito,Catherine Lombard Bohas,Edward M. Wolin,Eric Van Cutsem,Timothy J. Hobday,Takuji Okusaka,Jaume Capdevila,Elisabeth G.E. de Vries,Paola Tomassetti,Marianne Pavel,Sakina Hoosen,Tomas Haas,Jeremie Lincy,David Lebwohl,Kjell Öberg +16 more
TL;DR: Everolimus, as compared with placebo, significantly prolonged progression-free survival among patients with progressive advanced pancreatic neuroendocrine tumors and was associated with a low rate of severe adverse events.
Journal ArticleDOI
Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial
John J. Bissler,J. Christopher Kingswood,Elżbieta Radzikowska,Bernard A. Zonnenberg,Michael Frost,Elena Belousova,Matthias Sauter,Norio Nonomura,Susanne Brakemeier,Petrus J. de Vries,Vicky Whittemore,David Chen,Tarek Sahmoud,Gaurav D. Shah,Jeremie Lincy,David Lebwohl,Klemens Budde +16 more
TL;DR: Everolimus reduced angiomyolipoma volume with an acceptable safety profile, suggesting it could be a potential treatment for angiomeolipomas associated with tuberous sclerosis.
Journal ArticleDOI
A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy.
Sara A. Hurvitz,Florence Dalenc,Mario Campone,Ruth O'Regan,Vivianne C. G. Tjan-Heijnen,Joseph Gligorov,Antonio Llombart,Haresh Jhangiani,Hamid R. Mirshahidi,Elizabeth Tan-Chiu,Sara Miao,Mona El-Hashimy,Jeremie Lincy,Tetiana Taran,Jean-Charles Soria,Tarek Sahmoud,Fabrice Andre +16 more
TL;DR: The findings suggest that the combination of everolimus plus trastuzumab and paclitaxel is feasible, with promising activity in patients with highly resistant HER2-positive advanced breast cancer, currently under investigation in the BOLERO-1 phase 3 trial.
Journal ArticleDOI
Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary
Simron Singh,Carlo Carnaghi,Roberto Buzzoni,Rodney F. Pommier,Markus Raderer,Jiri Tomasek,Harald Lahner,Juan W. Valle,Maurizio Voi,Lida Bubuteishvili-Pacaud,Jeremie Lincy,Edward M. Wolin,Natsuko Okita,Steven K. Libutti,Do-Youn Oh,Matthew H. Kulke,Jonathan R. Strosberg,James C. Yao,Marianne Pavel,Nicola Fazio +19 more
TL;DR: Everolimus showed a clinically meaningful PFS benefit in patients with advanced progressive nonfunctional NET of GI and unknown primary, consistent with the overall RADIANT-4 results, providing an effective new standard treatment option in this patient population and filling an unmet treatment need for these patients.
Journal ArticleDOI
Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Impact of somatostatin analog use on progression-free survival in the RADIANT-3 trial.
Manisha H. Shah,Catherine Lombard-Bohas,Tetsuhide Ito,Edward M. Wolin,E. Van Cutsem,Carolin Sachs,Robert Winkler,Jeremie Lincy,T. Hobday,James C. Yao +9 more
TL;DR: Everolimus significantly prolonged PFS compared with placebo in patients with advanced pNET in this large phase III clinical trial, and was seen across all patient subgroups, including patients receiving prior and on-study SSA treatment.